Compare HCI & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | STOK |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | 594 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | HCI | STOK |
|---|---|---|
| Price | $176.64 | $29.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $230.00 | $39.20 |
| AVG Volume (30 Days) | 140.4K | ★ 773.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $7.67 | $77.49 |
| P/E Ratio | $9.97 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $136.37 | $12.25 |
| 52 Week High | $210.50 | $40.22 |
| Indicator | HCI | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 47.19 |
| Support Level | $176.10 | $28.22 |
| Resistance Level | $182.62 | $33.51 |
| Average True Range (ATR) | 4.75 | 1.64 |
| MACD | -1.12 | -0.11 |
| Stochastic Oscillator | 37.62 | 41.12 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.